Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been given a consensus rating of “Moderate Buy” by the twelve brokerages that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $11.58.

HCAT has been the subject of several research reports. Evercore ISI increased their price objective on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Stephens dropped their price target on Health Catalyst from $8.00 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Piper Sandler reduced their price objective on Health Catalyst from $14.00 to $11.00 and set an “overweight” rating for the company in a research report on Monday, August 26th. Cantor Fitzgerald reissued an “overweight” rating and issued a $16.00 target price on shares of Health Catalyst in a research report on Friday, October 4th. Finally, JPMorgan Chase & Co. boosted their target price on Health Catalyst from $10.00 to $13.00 and gave the company an “overweight” rating in a research note on Wednesday, September 4th.

Insider Buying and Selling

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Monday, August 5th. The shares were sold at an average price of $6.19, for a total value of $32,243.71. Following the completion of the sale, the chief operating officer now owns 150,006 shares in the company, valued at $928,537.14. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $6.19, for a total transaction of $32,243.71. Following the transaction, the chief operating officer now owns 150,006 shares of the company’s stock, valued at $928,537.14. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kevin Lee Freeman sold 7,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the completion of the sale, the insider now directly owns 255,881 shares of the company’s stock, valued at approximately $1,847,460.82. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,362 shares of company stock worth $256,009. Insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors and hedge funds have recently modified their holdings of HCAT. Nisa Investment Advisors LLC lifted its stake in shares of Health Catalyst by 461.0% during the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after buying an additional 5,232 shares during the last quarter. Quarry LP raised its holdings in Health Catalyst by 59.4% in the 2nd quarter. Quarry LP now owns 7,002 shares of the company’s stock valued at $45,000 after acquiring an additional 2,610 shares during the period. Perfromance Wealth Partners LLC bought a new position in Health Catalyst in the 2nd quarter valued at about $64,000. Mackenzie Financial Corp acquired a new stake in Health Catalyst during the second quarter worth approximately $70,000. Finally, EntryPoint Capital LLC bought a new stake in shares of Health Catalyst during the first quarter worth approximately $98,000. 85.00% of the stock is currently owned by institutional investors and hedge funds.

Health Catalyst Trading Up 3.7 %

NASDAQ:HCAT opened at $8.14 on Friday. Health Catalyst has a 1 year low of $5.42 and a 1 year high of $11.41. The stock has a 50-day moving average price of $7.49 and a two-hundred day moving average price of $6.90. The stock has a market cap of $492.23 million, a price-to-earnings ratio of -5.43 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.04. The business had revenue of $75.90 million during the quarter, compared to analyst estimates of $74.96 million. Health Catalyst had a negative return on equity of 9.38% and a negative net margin of 28.87%. Health Catalyst’s quarterly revenue was up 3.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.21) EPS. Sell-side analysts forecast that Health Catalyst will post -0.35 earnings per share for the current year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.